196 related articles for article (PubMed ID: 17961195)
1. Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?
Aagaard L; Soendergaard B; Stenver DI; Hansen EH
Br J Clin Pharmacol; 2008 Mar; 65(3):364-76. PubMed ID: 17961195
[TBL] [Abstract][Full Text] [Related]
2. Ontological Organization and Bioinformatic Analysis of Adverse Drug Reactions From Package Inserts: Development and Usability Study.
Li X; Lin X; Ren H; Guo J
J Med Internet Res; 2020 Jul; 22(7):e20443. PubMed ID: 32706718
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Three Different Data Sources of Adverse Drug Reactions Using Adverse Drug Reaction Data of Fluorouracil for Gastric Cancer as an Example.
Niu R; Chen Y; Xiang Y; Liu Y; Guo J; Feng B
Biol Pharm Bull; 2020; 43(10):1476-1480. PubMed ID: 32999157
[TBL] [Abstract][Full Text] [Related]
4. A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues.
Hasford J; Bruchmann F; Lutz M; Thürmann P; Schmiedl S
Eur J Clin Pharmacol; 2021 Nov; 77(11):1697-1704. PubMed ID: 34143228
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.
Ortega A; Aguinagalde A; Lacasa C; Aquerreta I; Fernández-Benítez M; Fernández LM
Ann Pharmacother; 2008 Oct; 42(10):1491-6. PubMed ID: 18780808
[TBL] [Abstract][Full Text] [Related]
7. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
[TBL] [Abstract][Full Text] [Related]
8. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.
Aagaard L; Hansen EH
BMC Clin Pharmacol; 2009 Mar; 9():4. PubMed ID: 19254390
[TBL] [Abstract][Full Text] [Related]
9. Safety learning from drugs of the same class: room for improvement.
Stefansdottir G; Knol MJ; Arnardottir AH; van der Elst ME; Grobbee DE; Leufkens HG; De Bruin ML
Clin Pharmacol Ther; 2012 May; 91(5):872-80. PubMed ID: 22453192
[TBL] [Abstract][Full Text] [Related]
10. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
11. Identification of discrepancies between adverse drug reactions coded by medical records technicians and those reported by the pharmacovigilance team in pediatrics: An intervention to improve identification, reporting, and coding.
Soyer J; Necsoiu D; Desjardins I; Lebel D; Bussières JF
Arch Pediatr; 2019 Oct; 26(7):400-406. PubMed ID: 31611146
[TBL] [Abstract][Full Text] [Related]
12. Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study.
Johansson ML; Hägg S; Wallerstedt SM
BMC Clin Pharmacol; 2011 Sep; 11():14. PubMed ID: 21899766
[TBL] [Abstract][Full Text] [Related]
13. ADR in Journals: Are They Translated into Regulatory Frameworks?
Kolupoti A; Chakraborty A; Shahistha K
Curr Drug Saf; 2022; 17(1):34-39. PubMed ID: 34151768
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
Issa AM
Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
[TBL] [Abstract][Full Text] [Related]
15. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
[TBL] [Abstract][Full Text] [Related]
16. Bias in spontaneous reporting of adverse drug reactions in Japan.
Matsuda S; Aoki K; Kawamata T; Kimotsuki T; Kobayashi T; Kuriki H; Nakayama T; Okugawa S; Sugimura Y; Tomita M; Takahashi Y
PLoS One; 2015; 10(5):e0126413. PubMed ID: 25933226
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and quality of adverse drug reaction reports by pharmacists in Norway.
Gedde-Dahl A; Harg P; Stenberg-Nilsen H; Buajordet M; Granas AG; Horn AM
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):999-1005. PubMed ID: 17457794
[TBL] [Abstract][Full Text] [Related]
18. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
[TBL] [Abstract][Full Text] [Related]
19. A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain.
Sweis D; Wong IC
Drug Saf; 2000 Aug; 23(2):165-72. PubMed ID: 10945377
[TBL] [Abstract][Full Text] [Related]
20. [Dealing with adverse drug reactions in dentistry. Procedures on encountering adverse drug reactions and goal of the Swiss Pharmacovigilance system].
Egger SS; Krähenbühl S; Schlienger RG
Schweiz Monatsschr Zahnmed; 2005; 115(12):1209-18. PubMed ID: 16408825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
